The National Urea Cycle Disorders Foundation, NUCDF, and Zevra Therapeutics are teaming up to launch an awareness campaign during the month of October to improve the diagnosis of urea cycle disorders. Their goal is to highlight the critical importance of promptly checking blood ammonia levels and using proper testing techniques. The campaign’s primary message is that a blood ammonia test, performed promptly and properly, can save lives. Downloadable campaign resources focus on Recognizing the signs of UCDs and promptly ordering a test and Following proper test procedures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics initiated with a Buy at Guggenheim
- Zevra Therapeutics price target raised to $21 from $19 at Roth MKM
- Zevra Therapeutics price target raised to $25 from $18 at Maxim
- Zevra Therapeutics initiated with an Outperform at JMP Securities
- Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC